Structural basis of TMPRSS11D specificity and autocleavage activation
Open Access
- 10 May 2025
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Abstract
Transmembrane Protease, Serine-2 (TMPRSS2) and TMPRSS11D are human proteases that enable SARS-CoV-2 and Influenza A/B virus infections, but their biochemical mechanisms for facilitating viral cell entry remain unclear. We show these proteases spontaneously and efficiently cleave their own zymogen activation motifs, activating their broader protease activity on cellular substrates. We determine TMPRSS11D co-crystal structures with a native and an engineered activation motif, revealing insights into its autocleavage activation and distinct substrate binding cleft features. Leveraging this structural data, we develop nanomolar potency peptidomimetic inhibitors of TMPRSS11D and TMPRSS2. We show that a broad serine protease inhibitor that underwent clinical trials for TMPRSS2-targeted COVID-19 therapy, nafamostat mesylate, was rapidly cleaved by TMPRSS11D and converted to low activity derivatives. In this work, we develop mechanistic insights into human protease viral tropism and highlight both the strengths and limitations of existing human serine protease inhibitors, informing future drug discovery efforts targeting these proteases.Keywords
All Related Versions
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (1U19AI171292-01)
- Killam doctoral Fellowship. Mitacs Elevate postdoctoral fellowship
This publication has 66 references indexed in Scilit:
- Human coronavirus HKU1 recognition of the TMPRSS2 host receptorCell, 2024
- Improving the selectivity of 3-amidinophenylalanine-derived matriptase inhibitorsEuropean Journal of Medicinal Chemistry, 2022
- Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2Journal of Biological Chemistry, 2022
- Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trialeClinicalMedicine, 2021
- Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.eClinicalMedicine, 2021
- D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 JunctionCell Reports, 2021
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- MolProbity: More and better reference data for improved all‐atom structure validationProtein Science, 2017
- Inhibition of influenza virus infection and hemagglutinin cleavage by the protease inhibitor HAI-2Biochemical and Biophysical Research Communications, 2014
- Crystal structure of enteropeptidase light chain complexed with an analog of the trypsinogen activation peptide 1 1Edited by R. HuberJournal of Molecular Biology, 1999